Thera-SAbDab

CEMIPLIMAB

>   Structural Summary
TherapeuticCemiplimab
TargetPDCD1
Heavy ChainEVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (August '23)Approved
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2018
INN Year Recommended2019
Companies InvolvedInovio Pharmaceuticals%3BISA Pharmaceuticals%3BRegeneron Pharmaceuticals%3BSanofi%3BSidney Kimmel Cancer Center%3BSillaJen Biotherapeutics%3BUniversity of Texas M. D. Anderson Cancer Center
Conditions ApprovedSquamous cell cancer
Conditions ActiveCervical cancer%3BNon-small cell lung cancer%3BBasal cell cancer%3BOropharyngeal cancer%3BProstate cancer%3BFallopian tube cancer%3BGlioblastoma%3BMultiple myeloma%3BOvarian cancer%3BPeritoneal cancer%3BSolid tumours%3BB-cell lymphoma%3BCancer%3BHead and neck cancer%3BMalignant melanoma%3BRenal cell carcinoma
Conditions Discontinuedna
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy